Stay updated on IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial page.

Latest updates to the IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded a prominent operating-status notice and a new version tag (v3.2.0), replacing the old version (v3.0.2).SummaryDifference2%

- Check28 days agoChange DetectedVersion bumped from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page now lists Revision: v3.0.2, replacing v3.0.1, and the Back to Top link has been removed.SummaryDifference0.1%

- Check50 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%

- Check57 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new drug information and resources related to uveal melanoma, as well as the inclusion of various facility names and locations across multiple countries. Notably, the previous drug information for Dacarbazine and Ipilimumab has been removed.SummaryDifference6%

- Check71 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMCgp100 vs Investigator Choice in Uveal Melanoma Clinical Trial page.